Attovia Therapeutics, Inc. (Nasdaq: ATTO) reported its financial results for the second quarter ended June 30, 2026, and provided an update on its clinical pipeline. The company announced preliminary clinical proof of concept for its lead candidate, ATTO-1310, in chronic pruritus and high-itch atopic dermatitis (AD).
ATTO-1310 is a half-life extended ATTOBODY-based Fc-fusion protein targeting the itch cytokine IL-31. The company reported that a single dose of ATTO-1310 resulted in rapid, deep itch relief in patients with chronic pruritus and high-itch AD, with consistent lesion control demonstrated in the AD patient population. Complete Phase 1b data are expected in the fourth quarter of 2026.
Following the preliminary results, Attovia plans to initiate two global Phase 2 studies in the first half of 2027: one for chronic pruritus of unknown origin and another for high-itch AD. Additionally, the company received clearance from the National Medical Products Administration (NMPA) in China to begin a Phase 1b trial for cholestatic pruritus associated with primary biliary cholangitis (PBC) or primary sclerosing cholangitis (PSC) via an expedited review pathway.
Regarding its broader pipeline, the company is advancing ATTO-2306, a bispecific antibody targeting IL-31 and IL-13, and ATTO-1091, a trispecific antibody targeting TL1A, IL-23p19, and integrin α4β7, through IND-enabling activities. Phase 1 initiation for both programs is planned for the first half of 2027. Attovia also noted that it has advanced ATTO-006, a conditional bispecific tissue-resident memory T cell survival blocker, toward development candidate nomination by year-end 2026.
On the corporate side, Attovia completed an upsized Initial Public Offering (IPO) in August 2026, generating aggregate gross proceeds of approximately $332.4 million. The company reported cash, cash equivalents, and marketable securities of $115.1 million as of June 30, 2026. The company stated that its current cash position, including the net proceeds from the IPO, will enable it to fund operations into 2030.
Financial results for the quarter ended June 30, 2026, showed collaboration revenue of $0.5 million, attributed to research and development services under the EndPath RadioTherapeutics license agreement. Research and development expenses were $18.9 million, compared to $13.6 million in the prior year, driven by clinical and manufacturing costs for ATTO-1310 and IND-enabling activities for ATTO-2306 and ATTO-1091. General and administrative expenses were $3.3 million. The company reported a net loss of $20.7 million for the quarter.
